A recent survey asked patients with primary and recurrent ovarian cancer to consider their reasons for choosing maintenance therapy following surgery and chemotherapy. READ MORE
A recent study assessed the hypothesis that prolonging the platinum-free interval with platinum-free chemotherapy may offer improved outcomes in patients with progressing ovarian cancer.
Patients with ovarian cancer who are responsive to platinum-based chemotherapy may experience more than double an increase in PFS with a specific maintenance therapy, regardless of their disease characterization.
Administration of a PARP inhibitor to patients with recurrent ovarian cancer after an initial response to platinum-based chemotherapy helps maintain quality of life during treatment.
Less than 20% of patients with a history of ovarian cancer meeting NCCN guidelines have undergone genetic testing or have discussed testing with their health care providers.
Research in Review
The treatment landscape in the coming decade for ovarian cancers will likely feature poly ADP ribose polymerase inhibitors in combination with other treatments.
Women with BRCA-mutated relapsed serous ovarian cancer who received maintenance therapy after platinum-based chemotherapy prolonged their progression-free survival by almost 7 months.
Patients receiving treatment for ovarian cancer experienced a significant out-of-pocket financial burden, due largely to cost disparities across treatment types and a lack of definitive treatment options.
A combination regimen involving standard carboplatin chemotherapy and a novel drug may improve overall survival for more than 50% of women with high-grade serous ovarian cancers.